Shionogi & Co., Ltd.

OSAKA, Japan--( BUSINESS WIRE )--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced Shionogi Inc., a New Jersey-based subsidiary of Shionogi, has been awarded a $375 million project agreement through the Rapid Response Partnership Vehicle (RRPV), to advance the development of S-892216, a 3CL protease inhibitor, as a long-acting injectable for COVID-19 pre-exposure prophylaxis. RRPV is a consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). This project award will address a gap for pre-exposure prophylaxis therapeutics that have the potential to provide protection against severe outcomes of COVID-19. Shionogi plans to file an investigational new drug application in the U.S. and begin phase 1 studies this year. “COVID-19 continues to be a serious global health risk even with available vaccines and treatments. We share BARDA’s recognition of this unmet need and appreciate its selection of S-892216 for this important program,” said John Keller, Ph.D., Senior Executive Officer, Senior Vice President, R&D Supervisory Unit at Shionogi. “With our deep expertise in antiviral drug development, continually expanding knowledge of COVID-19 and support from BARDA, we will advance the pre-exposure prophylaxis program for S-892216 at pace with public health needs.” This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under Other Transaction Number: 75A50123D00005. About S-892216 S-892216, an investigational second generation 3CL protease inhibitor, is being developed both as a long-acting injectable and as an oral drug, intended for prophylaxis and treatment of SARS-CoV-2 infection respectively. In pre-clinical trials, S-892216 demonstrated a strong antiviral effect. S-892216 was discovered by Shionogi and its research and development is supported by the Japan Agency for Medical Research and Development (AMED) under Grant Numbers JP21fk0108584 and 22fk0108522h0001. The S-892216 oral formulation is being studied in a Phase 1 clinical trial in Japan to evaluate the pharmacokinetics, safety, and tolerability in healthy adults. A Phase 1 clinical trial with the long-acting injectable formulation is expected to begin in 2025. In addition to S-892216, Shionogi continues its extensive global development program for the novel COVID-19 oral antiviral ensitrelvir (generic name: ensitrelvir fumaric acid, Code No.: S-217622), known as Xocova® 125 mg tablet in Japan. Ensitrelvir was granted Fast Track designation by the U.S. Food and Drug Administration in 2023 and it was approved in Singapore based on the Special Access Route application in 2023. It remains an investigational drug outside of Japan and Singapore. About Shionogi in Infectious Disease Shionogi is committed to “Protect people worldwide from the threat of infectious diseases” with research and development of therapeutics, whilst also working towards total care through awareness building, epidemiologic monitoring, prevention, diagnosis, and addressing exacerbations, as well as treating infections directly. As SARS-CoV-2 continues to have a major impact on people’s lives and to represent a global threat, Shionogi will seek to contribute to re-establishing the safety and security of society by developing new products and services to address this pandemic. Shionogi is committed to equitable access worldwide, including by working with the Medicines Patent Pool to provide access to low- and middle-income countries (LMICs) , and by strengthening its manufacturing and global supply chain. Forward-Looking Statements This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also, for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

OSAKA, Japan, December 23, 2024 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") today announced that, at a meeting held on December 23, 2024, its Board of Directors, resolved to acquire all shares of the Ping An-Shionogi Co., Ltd. and Ping An-Shionogi (Hong Kong) Limited. joint ventures with subsidiaries of Ping An Insurance (Group) Company of China, Ltd. (Headquarters: Guangdong Province, China; hereinafter "Ping An"), thereby dissolving the joint ventures and making both companies wholly-owned subsidiaries. I. Reason for Dissolution of the Joint Venture On July 24, 2020, Shionogi entered into an agreement to establish a joint venture with two subsidiaries of Ping An: Ping An Life Insurance Company of China, Ltd. (headquartered in Guangdong, China, hereinafter "Ping An Life") and Tutum Japan Healthcare Limited (headquartered in the Cayman Islands, hereinafter "Ping An Overseas"), an indirect subsidiary of Ping An and a subsidiary of China Ping An Insurance Overseas (Holdings) Limited. The agreement was made between these entities and our subsidiary, Shionogi (Hong Kong) Co., Ltd. (headquartered in Hong Kong, hereinafter "Shionogi (Hong Kong)"). The joint ventures, Ping An-Shionogi Co., Ltd. and Ping An-Shionogi (Hong Kong) Limited., were established in Shanghai and Hong Kong to engage in joint business activities in Asia, including China 1, 2, 3. In China, Ping An-Shionogi Co., Ltd. and Ping An-Shionogi (Hong Kong) Limited., since their establishment, have made progress with certain Shionogi original drugs such as a New Drug Application and early use in medical special zones of cefiderocol, an antibiotic for Gram-negative bacterial infections 4, 5, and in Singapore, the approval of ensitrelvir (product name in Japan: Xocova® Tablets 125 mg) and cefiderocol based on SAR* applications 6, 7. Regarding our initial goal of utilizing AI for drug discovery in China, we have achieved significant results through our collaboration with Ping An. By combining Ping An’s advanced AI technology with Shionogi’s expertise in drug discovery, we have generated multiple development candidates. After reviewing the joint venture business plan in the context of the business strategies of both Shionogi and Ping An, it was concluded that it would enhance the corporate value of both companies and contribute more to society if Shionogi focused on the research, development, sales, and manufacturing of new drugs in China and Ping An concentrated on its core businesses. Therefore, it was agreed to amicably dissolve the joint venture business. Shionogi will continue to strive to contribute to patients and healthcare in China and Asia and will work to promote its business in these regions. * SAR (Special Access Route): A pharmaceutical system unique to Singapore for importing and supplying unapproved therapeutic drugs. II. Details of the Dissolution of the Joint Ventures i. Content of the Dissolved Joint Venture Business and Method of Transfer of Shares Shionogi and Ping An have agreed to dissolve their two joint ventures. Shionogi (Hong Kong) will acquire the 49% share held by Ping An Life in Ping An-Shionogi Co., Ltd., which conducts pharmaceutical research, development, manufacturing, and sales in China. Additionally, through this transfer agreement, Shionogi (Hong Kong) will acquire the 49% share held by Ping An Overseas Holdings in Ping An-Shionogi (Hong Kong) Limited., which handles IP license management and product import/export operations across Asia. ii. Outline of the Joint Ventures (1) Outline of Ping An-Shionogi Co., Ltd., (1) Name of Company Ping An-Shionogi Co., Ltd. (2) Location Room 602 Kaibin Centre, No. 199 Kaibin Road, Xuhui District, Shanghai, China (3) Representative Tatsumori Yoshida, Chairman and CEO (4) Business Description Investment, pharmaceuticals, clinical-laboratory drugs/instruments research, development, sale, etc., IT-related technology development, services (5) Registered Capital JPY 63,180 million (6) Date of Founding November 2020 (7) Fiscal-year End December (8) Net Assets JPY 24,791 million (Consolidated) (9) Total Assets JPY 28,249 million (Consolidated) (10) Shareholders Shionogi (Hong Kong) 51%, Ping An Life 49% (1) Name of Company Ping An-Shionogi Co., Ltd. (2) Location Room 602 Kaibin Centre, No. 199 Kaibin Road, Xuhui District, Shanghai, China (3) Representative Tatsumori Yoshida, Chairman and CEO (4) Business Description Investment, pharmaceuticals, clinical-laboratory drugs/instruments research, development, sale, etc., IT-related technology development, services (5) Registered Capital JPY 63,180 million (6) Date of Founding November 2020 (7) Fiscal-year End December (8) Net Assets JPY 24,791 million (Consolidated) (9) Total Assets JPY 28,249 million (Consolidated) (10) Shareholders Shionogi (Hong Kong) 51%, Ping An Life 49% Exchange rates are based on the interim rate of JPY 100 = RMB 4.6549 as of December 31, 2023, as announced by the Bank of China. (2) Outline of Ping An- Shionogi (Hong Kong) Limited., (1) Name of Company Ping An-Shionogi (Hong Kong) Limited. (2) Location Room 802, The Gateway Tower 1, Harbour City, 25 Canton Road, Tsim Sha Tsui, Kowloon, Hong Kong, China (3) Representative Tatsumori Yoshida, Chairman and CEO (4) Business Description Equity investment, financial services, IP license management, import/export of products from/to Asian countries (5) Capital JPY 6,220 million (6) Date of Founding August 2020 (7) Fiscal-year End March (8) Net Assets JPY 7,061 million (9) Total Assets JPY 14,055 million (10) Shareholders Shionogi (Hong Kong) 51%, Ping An Overseas 49% (1) Name of Company Ping An-Shionogi (Hong Kong) Limited. (2) Location Room 802, The Gateway Tower 1, Harbour City, 25 Canton Road, Tsim Sha Tsui, Kowloon, Hong Kong, China (3) Representative Tatsumori Yoshida, Chairman and CEO (4) Business Description Equity investment, financial services, IP license management, import/export of products from/to Asian countries (5) Capital JPY 6,220 million (6) Date of Founding August 2020 (7) Fiscal-year End March (8) Net Assets JPY 7,061 million (9) Total Assets JPY 14,055 million (10) Shareholders Shionogi (Hong Kong) 51%, Ping An Overseas 49% Exchange rates are based on the interim rate of JPY 100 = HKD 5.82 as of December 31, 2023, as announced by the Hong Kong Monetary Authority. III. Outline of the Other Parties to the Joint Ventures (1) Ping An Shionogi Co., Ltd., (as of December 31, 2023) (1) Name of Company Ping An Life Insurance Company of China, Ltd. (2) Location 14th, 15th, 16th, 37th, 41st, 44th, 45th and 46th Floors, Ping An Finance Center, No.5033 Yi Tian Road, Futian District, Shenzhen, Guangdong Province, China (3) Representative Yang Zheng, Chairman (4) Business Description Life insurance (5) Capital JPY 527,416 million (6) Date of Founding December 17, 2002 (7) Number of Shares Issued 33,800,000,000 shares (8) Fiscal-year End December (9) Number of Employees 48,556 (10) Main Customers Private individuals (11) Main Banks Bank of China, Industrial and Commercial Bank of China, China Construction Bank, Ping An Bank (12) Major Shareholders and Shareholding Ratios Ping An Insurance (Group) Company of China, Ltd. 99.51% (13) Relationship Between the Parties Capital Relationship The company holds 6,356,000 shares of Shionogi’s common stock, which represents 2.21% of the issued shares. Personal Relationship There is no relationship to be disclosed between the parties. Transactional Relationship There is no relationship to be disclosed between the parties. Status as Related Party There is no relationship to be disclosed between the parties. (14) The consolidated financial performance and financial position of the company for the past three years. (million JPY) Fiscal-year End December, 2021 December, 2022 December, 2023 Net Sales 13,707,480 6,597,054 7,583,173 Operating Income 1,082,838 1,576,940 1,452,113 (1) Name of Company Ping An Life Insurance Company of China, Ltd. (2) Location 14th, 15th, 16th, 37th, 41st, 44th, 45th and 46th Floors, Ping An Finance Center, No.5033 Yi Tian Road, Futian District, Shenzhen, Guangdong Province, China (3) Representative Yang Zheng, Chairman (4) Business Description Life insurance (5) Capital JPY 527,416 million (6) Date of Founding December 17, 2002 (7) Number of Shares Issued 33,800,000,000 shares (8) Fiscal-year End December (9) Number of Employees 48,556 (10) Main Customers Private individuals (11) Main Banks Bank of China, Industrial and Commercial Bank of China, China Construction Bank, Ping An Bank (12) Major Shareholders and Shareholding Ratios Ping An Insurance (Group) Company of China, Ltd. 99.51% (13) Relationship Between the Parties Capital Relationship The company holds 6,356,000 shares of Shionogi’s common stock, which represents 2.21% of the issued shares. Personal Relationship There is no relationship to be disclosed between the parties. Transactional Relationship There is no relationship to be disclosed between the parties. Status as Related Party There is no relationship to be disclosed between the parties. (14) The consolidated financial performance and financial position of the company for the past three years. (million JPY) Fiscal-year End December, 2021 December, 2022 December, 2023 Net Sales 13,707,480 6,597,054 7,583,173 Operating Income 1,082,838 1,576,940 1,452,113 Exchange rates are based on the interim rate of JPY 100 = RMB 4.6549 as of December 31, 2023, as announced by the Bank of China. (2) Other Party to Ping An Shionogi (Hong Kong) Co., Ltd., (as of December 31, 2023) (1) Name of Company Tutum Japan Healthcare Limited (2) Location 4th Floor, Harbour Place, 103 South Church Street, P.O. Box 10240, Grand Cayman KY1-1002, Cayman Islands (3) Representative KUI Kaipin, Director (4) Business Description Investment Holding (5) Capital JPY 4,000,000,000 (6) Date of Founding March 29, 2019 (7) Number of Shares Issued 3 (8) Fiscal-year End December (9) Number of Employees N/A (10) Main Customers N/A (11) Main Banks Bank of China (12) Major Shareholders and Shareholding Ratios 100% held by China Ping An Insurance Overseas (Holdings) Limited (13) Relationship Between the Parties Capital Relationship There is no relationship to be disclosed between the parties. Personal Relationship There is no relationship to be disclosed between the parties. Transactional Relationship There is no relationship to be disclosed between the parties. Status as Related Party There is no relationship to be disclosed between the parties. (1) Name of Company Tutum Japan Healthcare Limited (2) Location 4th Floor, Harbour Place, 103 South Church Street, P.O. Box 10240, Grand Cayman KY1-1002, Cayman Islands (3) Representative KUI Kaipin, Director (4) Business Description Investment Holding (5) Capital JPY 4,000,000,000 (6) Date of Founding March 29, 2019 (7) Number of Shares Issued 3 (8) Fiscal-year End December (9) Number of Employees N/A (10) Main Customers N/A (11) Main Banks Bank of China (12) Major Shareholders and Shareholding Ratios 100% held by China Ping An Insurance Overseas (Holdings) Limited (13) Relationship Between the Parties Capital Relationship There is no relationship to be disclosed between the parties. Personal Relationship There is no relationship to be disclosed between the parties. Transactional Relationship There is no relationship to be disclosed between the parties. Status as Related Party There is no relationship to be disclosed between the parties. (3) Outline of Parent Company of Other Parties to the Joint Ventures (as of December 31, 2023) (1) Name of Company Ping An Insurance (Group) Company of China, Ltd. (2) Location Ping An Finance Center, No. 5033 Yi Tian Road, Futian District, Shenzhen, Guangdong Province, China (3) Representative Ma Mingzhe, Chairman (4) Business Description Insurance Business, Banking Business, Asset Management Business, Technology Business (5) Capital JPY 391,205 million (6) Date of Founding March 21, 1988 (7) Number of Shares Issued 10,762,657,695 A-Shares, 7,447,576,912 H-Shares (8) Fiscal-year End December (9) Number of Employees 288,751 (10) Main Customers ― (11) Main Banks ― (12) Major Shareholders and Shareholding Ratios CP Group Ltd. 5.84% (H-Shares) Shenzhen Investment Holdings Co., Ltd. 5.29% (A-Shares) (13) Relationship Between the Parties Capital Relationship There is no relationship to be disclosed between the parties. Personal Relationship There is no relationship to be disclosed between the parties. Transactional Relationship There is no relationship to be disclosed between the parties. Status as Related Party There is no relationship to be disclosed between the parties. (14) The consolidated financial performance and financial position of the company for the past three years. (million JPY) Fiscal-year End December, 2021 December, 2022 December, 2023 Net Sales 25,359,169 18,912,436 19,630,690 Operating Income 3,000,816 3,068,572 2,596,253 (1) Name of Company Ping An Insurance (Group) Company of China, Ltd. (2) Location Ping An Finance Center, No. 5033 Yi Tian Road, Futian District, Shenzhen, Guangdong Province, China (3) Representative Ma Mingzhe, Chairman (4) Business Description Insurance Business, Banking Business, Asset Management Business, Technology Business (5) Capital JPY 391,205 million (6) Date of Founding March 21, 1988 (7) Number of Shares Issued 10,762,657,695 A-Shares, 7,447,576,912 H-Shares (8) Fiscal-year End December (9) Number of Employees 288,751 (10) Main Customers ― (11) Main Banks ― (12) Major Shareholders and Shareholding Ratios CP Group Ltd. 5.84% (H-Shares) Shenzhen Investment Holdings Co., Ltd. 5.29% (A-Shares) (13) Relationship Between the Parties Capital Relationship There is no relationship to be disclosed between the parties. Personal Relationship There is no relationship to be disclosed between the parties. Transactional Relationship There is no relationship to be disclosed between the parties. Status as Related Party There is no relationship to be disclosed between the parties. (14) The consolidated financial performance and financial position of the company for the past three years. (million JPY) Fiscal-year End December, 2021 December, 2022 December, 2023 Net Sales 25,359,169 18,912,436 19,630,690 Operating Income 3,000,816 3,068,572 2,596,253 Exchange rates are based on the interim rate of JPY 100 = RMB 4.6549 as of December 31, 2023, as announced by the Bank of China. IV. Schedule Dissolution Date (Stock Acquisition Date) Ping An-Shionogi Co., Ltd.: March 2025 (planned) Ping An-Shionogi (Hong Kong) Limited.: January 2025 (planned) V. Future Outlook Following the dissolution of the joint ventures and the acquisition of all shares in the joint venture companies by Shionogi (Hong Kong), Ping An Shionogi Co., Ltd. and Ping An-Shionogi (Hong Kong) Limited. will become 100% subsidiaries of Shionogi. In the future, we will fully integrate the two joint ventures as wholly owned subsidiaries, while accelerating our focus on the new drug business. At the same time, we will establish a new structure that can contribute to the globalization of the SHIONOGI Group. Additionally, Shionogi Healthcare Co., Ltd. (currently a 100% subsidiary of Ping An-Shionogi (Hong Kong) Limited. is expected to become a 100% subsidiary of Shionogi. Forward-Looking Statements This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. For Further Information, Contact: SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html References 1. Press Release: March 30, 2020 Notice Regarding the Signing of the Basic Agreement with Ping An Insurance for a Capital and Business Alliance including the Disposal of Treasury Shares by Way of Third-Party Allotment 2. Press Release: July 13, 2020 Notice Regarding the Signing of the Agreements on the Establishment of the Joint Ventures with Ping An Insurance, the Establishment of a New Subsidiary, the Signing of the Agreements on Transfer of Subsidiary Shares and Equity Stakes, and the Disposal of Treasury Shares by Way of Third-Party Allotment 3. Press Release: July 27, 2020 Notice Regarding the Execution of the Agreements on the Establishment of the Joint Ventures with Ping An and the Disposal of Treasury Shares by Way of Third-Party Allotment 4. Press Release: January 31, 2024 Cefiderocol is approved for clinical use in Boao Lecheng International Medical Tourism Pilot Zone, Hainan, China 5. Press Release: August 5, 2024 New Drug Application of Novel Siderophore Cephalosporin Antibiotics, Cefiderocol, Accepted in China 6. Press Release: December 19, 2023 Execution of Sub-license Agreement from Ping An-Shionogi Hong Kong to Juniper Therapeutics and SAR approval in Singapore regarding ensitrelvir fumaric acid, a treatment drug for the novel coronavirus infection (COVID-19) 7. 1st Quarter of Fiscal 2024 Financial Results, page 9

Tokyo, Japan and Cambridge, UK, 19 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Shionogi & Co., Ltd. (“Shionogi”) today announce that QUVIVIQ™ (daridorexant) 25 and 50 mg has been launched and is now available in Japan as a new treatment for adults with insomnia. QUVIVIQ™ is an oral Dual Orexin Receptor Antagonist (DORA) for the treatment of insomnia that selectively binds to receptors of the wake-promoting neuropeptide orexin (OX1R and OX2R), inhibiting excessive wakefulness and facilitating the transition to sleep. Nxera Pharma Japan Co., Ltd. (a wholly owned subsidiary of Nxera Pharma) is the approval holder and will be responsible in part for provision of drug product. Shionogi will be solely responsible for distribution and sales activities for QUVIVIQ™ in Japan under the commercial partnership agreement with Nxera Pharma announced on 1 October 2024. For Nxera, reaching this important milestone highlights its ability to develop novel therapeutics for patients in Japan and reinforces its ambition to be a partner of choice for companies looking to develop and commercialize new therapeutics for the Japanese market. As a new pillar, Shionogi is focusing on the 'QOL disease area,' which is less affected by trends. Starting with the launch of QUVIVIQ™, Shionogi is working to strengthen the 'QOL disease area' as a solid pillar. Together, Nxera and Shionogi are committed to deliver QUVIVIQ™ as quickly as possible as a product that has the potential to meet the needs of insomnia patients for a long time to come. –END– Notes to Editors Product Information Product nameQUVIVIQ™ 25 mg, 50 mgNon-proprietary namedaridorexantIndicationInsomniaDosage regimenThe usual adult dosage is 50 mg of daridorexant to be taken orally once daily immediately before bedtime. In addition, depending on the patient's condition, 25 mg can be administered once daily.Date of approval24 September 2024Date of NHI price listing20 November 2024Date of launch19 December 2024Drug priceJPY57.30 per 25 mg tabletJPY90.80 per 50 mg tabletApproval holderNxera Pharma Japan Co., Ltd.DistributorShionogi & Co., Ltd. About QUVIVIQ™QUVIVIQ™ (daridorexant) is a dual orexin receptor antagonist, discovered by Idorsia Pharmaceuticals Ltd, that blocks the binding and activity of the wake-promoting neuropeptides known as orexins. In October 2022, daridorexant achieved positive Phase 3 top-line results in Japanese patients with insomnia and Nxera Pharma Japan has obtained the manufacturing and marketing approval in Japan for QUVIVIQ™ as a treatment for adult patients with insomnia, as of September 24, 2024. Daridorexant is approved in the US, Europe and Canada, and marketed in these territories under the brand name QUVIVIQ™ by Idorsia Pharmaceuticals Ltd. * QUVIVIQ™ is a trademark of Idorsia Ltd. About Insomnia DisorderInsomnia disorder is defined as difficulty initiating or maintaining sleep, causing clinically significant distress or impairment in important areas of daytime functioning. As defined this impact on sleep quantity or quality should be present for at least three nights per week, lasts for at least three months, and occurs despite an adequate opportunity to sleep. Insomnia is a condition of overactive wake signaling and studies have shown that areas of the brain associated with wakefulness remain more active during sleep in patients with insomnia. According to a survey by Japan’s Ministry of Health, Labour and Welfare in 2018, about 20% of Japanese adults struggle to get enough rest from sleep. Insomnia as a disorder is quite different from a brief period of poor sleep, and it can take its toll on both physical and mental health. It is a persistent condition with a negative impact on daytime functioning. Research has shown that poor quality sleep can affect many aspects of daily life, including the ability to concentrate, mood, and energy levels. The goal of treatments for insomnia is to improve sleep quality and quantity, as well as daytime functioning, while avoiding adverse events and next-morning residual effects. Current recommended treatment of insomnia includes sleep hygiene therapy, cognitive behavioral therapy, and pharmacotherapy. About ShionogiShionogi strives constantly to supply the best possible medicine (healthcare solutions) to protect the health and wellbeing of the patients we serve, and as a united group. We have identified Contributing to a Healthy and Prosperous Life as a material focus. We are committed to creating a society where everyone can lead a longer, more vibrant life, realizing their goals.For more information, please visit https://www.shionogi.com/global/en/ About Nxera PharmaNxera Pharma (formerly Sosei Heptares) is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases, and leverages the power of our unique and industry leading GPCR-targeted structure-based drug discovery NxWave™ platform to provide a sustainable source of best- or first-in-class candidates. Nxera employs over 350 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit www.nxera.life LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Enquiries: Nxera – Media and Investor RelationsKentaro Tahara, VP Investor Relations and Corporate StrategyShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager+81 (0)3 5210 3399 | +44 (0)1223 949390 |IR@Nxera.life MEDiSTRAVA (for International Media)Mark Swallow, Frazer Hall, Erica Hollingsworth+44 (0)203 928 6900 | Nxera@medistrava.com Forward-looking statementsThis press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.